Enovid

E411214

Enovid was the first commercially available oral contraceptive pill, introduced in the 1960s and widely recognized for revolutionizing birth control and reproductive health.

All labels observed (1)

Label Occurrences
Enovid canonical 2

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf combination oral contraceptive ⓘ
hormonal contraceptive ⓘ
oral contraceptive pill ⓘ
pharmaceutical drug ⓘ
approvedBy U.S. Food and Drug Administration ⓘ
associatedRisk cardiovascular side effects ⓘ
increased risk of thromboembolic events ⓘ
associatedWith changes in U.S. contraceptive regulation ⓘ
early debates over contraceptive safety ⓘ
containsHormoneType estrogen ⓘ
progestin ⓘ
containsSyntheticEstrogen mestranol ⓘ
containsSyntheticProgestin norethynodrel ⓘ
countryOfFirstApproval United States ⓘ
developedBy G. D. Searle & Company ⓘ
estrogenComponent mestranol ⓘ
FDAApprovalYear 1960 ⓘ
firstApprovedUse contraception ⓘ
hasActiveIngredient mestranol ⓘ
norethynodrel ⓘ
historicalSignificance catalyst of the sexual revolution ⓘ
influenced women’s rights movement ⓘ
influencedDevelopmentOf later low-dose oral contraceptives ⓘ
innovationType first-generation oral contraceptive ⓘ
introducedDecade 1960s ⓘ
legacy established oral contraception as a standard method of birth control ⓘ
legalStatusAtApproval prescription-only medicine ⓘ
manufacturer G. D. Searle & Company ⓘ
marketImpact rapid adoption among women seeking reliable birth control ⓘ
mechanismOfAction alteration of cervical mucus ⓘ
changes in endometrial lining ⓘ
inhibition of ovulation ⓘ
notableFor first commercially available oral contraceptive pill ⓘ
major impact on reproductive health ⓘ
revolutionizing birth control ⓘ
pharmaceuticalForm tablet ⓘ
pharmacologicalClass steroid hormone preparation ⓘ
previousIndication endometriosis ⓘ
infertility related to ovulatory disorders ⓘ
menstrual disorders ⓘ
primaryEffect prevention of pregnancy ⓘ
progestinComponent norethynodrel ⓘ
reasonForWithdrawal safety concerns related to high hormone doses ⓘ
regulatoryStatus withdrawn from market ⓘ
routeOfAdministration oral ⓘ
targetPopulation women of reproductive age ⓘ
therapeuticClass combined estrogen–progestin contraceptive ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.